Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Rosenberg

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|May 21, 2020
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancerZia Khan, Flavia Di Nucci, Antonia Kwan, et al.
Cancer|March 5, 2013
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working GroupMatthew D Galsky, Ryan Hendricks, Robert Svatek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2019
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort ResultsPadmanee Sharma, Arlene Siefker-Radtke, Filippo de Braud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial CarcinomaJonathan Rosenberg, Srikala S Sridhar, Jingsong Zhang, et al.
Cancer Medicine|February 28, 2015
HER2 as a target in invasive urothelial carcinomaJoaquim Bellmunt, Lillian Werner, Aristotle Bamias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 TherapyJarushka Naidoo, Xuan Wang, Kaitlin M Woo, et al.
Cancer Cell|November 22, 2024
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockadeHabib Hamidi, Yasin Senbabaoglu, Niha Beig, et al.
Advances in Anatomic Pathology|June 15, 2021
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial CancersEva Compérat, Mahul B Amin, Jonathan I Epstein, et al.
Advances in Anatomic Pathology|June 15, 2021
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of NeoplasiaMahul B Amin, Eva Comperat, Jonathan I Epstein, et al.
Genome Medicine|June 1, 2021
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patientsDana W Y Tsui, Michael L Cheng, Maha Shady, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Proceedings of the National Academy of Sciences of the United States of America|May 21, 2020
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancerZia Khan, Flavia Di Nucci, Antonia Kwan, et al.
Cancer|March 5, 2013
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working GroupMatthew D Galsky, Ryan Hendricks, Robert Svatek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2019
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort ResultsPadmanee Sharma, Arlene Siefker-Radtke, Filippo de Braud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial CarcinomaJonathan Rosenberg, Srikala S Sridhar, Jingsong Zhang, et al.
Cancer Medicine|February 28, 2015
HER2 as a target in invasive urothelial carcinomaJoaquim Bellmunt, Lillian Werner, Aristotle Bamias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 TherapyJarushka Naidoo, Xuan Wang, Kaitlin M Woo, et al.
Cancer Cell|November 22, 2024
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockadeHabib Hamidi, Yasin Senbabaoglu, Niha Beig, et al.
Advances in Anatomic Pathology|June 15, 2021
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial CancersEva Compérat, Mahul B Amin, Jonathan I Epstein, et al.
Advances in Anatomic Pathology|June 15, 2021
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of NeoplasiaMahul B Amin, Eva Comperat, Jonathan I Epstein, et al.
Genome Medicine|June 1, 2021
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patientsDana W Y Tsui, Michael L Cheng, Maha Shady, et al.
Pageof 8